Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.04 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.06, with a volume of 28,393 shares trading hands.
Mateon Therapeutics Price Performance
The company has a 50 day simple moving average of $0.04 and a 200 day simple moving average of $0.04.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- How to Invest in the Best Canadian Stocks
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- Investing in Travel Stocks Benefits
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
